U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 214094
Company: BIOCRYST
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
ORLADEYO BEROTRALSTAT HYDROCHLORIDE EQ 110MG BASE CAPSULE;ORAL Prescription None Yes No
ORLADEYO BEROTRALSTAT HYDROCHLORIDE EQ 150MG BASE CAPSULE;ORAL Prescription None Yes Yes
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
12/03/2020 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD; Orphan Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/214094Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000TOC.cfm
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
10/21/2024 SUPPL-3 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214094s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/214094Orig1s003ltr.pdf
11/21/2023 SUPPL-2 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214094s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/214094Orig1s002ltr.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
10/21/2024 SUPPL-3 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214094s003lbl.pdf
11/21/2023 SUPPL-2 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214094s002lbl.pdf
12/03/2020 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf
Back to Top